Albumin is a type of protein that circulates in your blood. When high levels of albumin appear in your urine, it can be an indicator of kidney disease. Treatment can include medication and diet ...

The primary efficacy endpoint is the change in proteinuria as evaluated by urine protein to creatinine ratio (UPCR) through 36 weeks in an interim analysis of at least 200 participants.

We also anticipate more support for tech innovation and self-sufficiency, and monetary easing in the form of more cuts to its reserve requirement ratio (100-200bps) and policy rate (30-50bps). However ...

The kidney failure risk equation (KRFE) helps predict a person’s risk of kidney failure. Doctors may use it to guide treatment decisions for people with mid to late stage chronic kidney disease ...

5 National Yang Ming Chiao Tung University School of Medicine, Taipei, Taiwan Objective Stromal barriers, such as the abundant desmoplastic stroma that is characteristic of pancreatic ductal ...

Department of Chemistry, Vancouver Island University, Nanaimo, BC V9R 5S5, Canada Department of Chemistry, University of Victoria, Victoria, BC V8W 2Y2, Canada ...

This document is Annex B of the 2025/26 NHS Payment Scheme (NHSPS). A currency is a way of grouping patients or activities into units that are clinically similar and have broadly similar resource ...

The study included patients with biopsy confirmed native kidney C3G who had a urine protein-to-creatinine ratio (UPCR) of at least 1g/g and an estimated glomerular filtration rate (eGFR ...

In the phase 3 Align trial, Vanrafia led to a 36% reduction in proteinuria as measured by the urine protein-to-creatinine ratio (UPCR) compared with placebo after 36 weeks of treatment.

Atrasentan reduced urine protein-to-creatinine ratio by 38% compared with 3% for placebo at week 36. The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia ...